Janssen buys into Idorsia drug | December 18, 2017 Issue - Vol. 95 Issue 49 | Chemical & Engineering News
Volume 95 Issue 49 | p. 15 | Concentrates
Issue Date: December 18, 2017

Janssen buys into Idorsia drug

Department: Business
Keywords: Pharmaceuticals, Janssen, Idorsia

Janssen, the research arm of Johnson & Johnson, has opted into the development of Idorsia’s blood pressure drug aprocitentan. The decision, which grants Janssen global rights to the compound and its derivatives, triggers a payment of $230 million to the Swiss biotech firm. Aprocitentan, a small-molecule dual endothelin receptor antagonist, is for people whose high blood pressure can’t be sufficiently lowered by other medicines. Idorsia is developing a Phase III study of the drug, set to begin next year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment